Biota Holdings Limited

ASX:BTA ISIN:AU000000BTA1

Feb 10, 2012

ÜBERBLICK | NEWS | MULTIMEDIA | FORSCHUNG

Biota Holdings Limited Company Summary

Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza.

Biota research breakthroughs have included a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease, licensed to MedImmune Inc. and novel nucleoside analogues designed to treat hepatitis C virus (HCV) infections, licensed to Boehringer Ingelheim. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems. In addition, Biota has a key partnership with Daiichi-Sankyo for the development of second generation influenza antivirals. Inverness Medical markets Biota's co-developed OIA FLU influenza diagnostics.

Relenza(tm) is a registered trademark of the GlaxoSmithKline group of companies.
BioStar(R) OIA(R) FLU and BioStar(R) OIA(R) FLU A/B are registered trademarks of Inverness Medical.

*Further information available at www.biota.com.au.

COMPANY DATA

	Headquarters	Unit 10, 585 Blackburn Road

		NOTTING HILL VIC 3168

		Australia

	Telephone	+61 3 9915 3700

	Fax	+61 3 9915 3702

	Principal Sector	Gesundheit & Pharm

	Principal Industry	Biotechnology

	Listed	1985/12/20

	Homepage	www.biota.com.au

Key Developments: Biota Holdings Limited

	Australischen Marktbericht der 30. März: Einen Rückgang nach Wochen der Markterhohlung MAR 30, 2009 13:00 - Article Views: 7,765 Die australische Aktien haben etwas höher geschlossen, die durch die Bergleute verstärkt wurden. Der Benchmark S&P/ASX200 Index endete der Tag um 0,7% oder 25,7 Punkte auf 3672,3 höher, während die breiteren ALL ORDINARIES Index stieg um 0,8% oder 29,3 Punkte auf 3615,6. Für die Woche sind die ASX200 und der ALL ORDINARIES um 6.0% und 6,2% beziehungsweise gestiegen.